Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOA101 in advanced solid tumors
NCT07055594Phase 2Recruiting
- Sponsor
- Shine-On Biomedical
- Start
- Jul 2025
- Primary completion
- Feb 2028
- Modality
- Antibody-Drug Conjugates (ADCs), Nanobodies (VHH), Trispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SOA101 in non-small cell lung cancer (NSCLC), ovarian cancer, head and neck carcinoma (HNC), breast cancer, colorectal cancer (CRC), sponsored by Shine-On Biomedical. Started Jul 2025; status: recruiting.
02
Drugs
SOA101
03
Conditions
non-small cell lung cancer (NSCLC)ovarian cancerhead and neck carcinoma (HNC)breast cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07055594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07055594.